Trem2-expressing multinucleated giant macrophages are a biomarker of good prognosis in head and neck squamous cell carcinoma.


Journal

Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693

Informations de publication

Date de publication:
16 Sep 2024
Historique:
accepted: 12 09 2024
received: 05 01 2024
revised: 01 07 2024
medline: 13 9 2024
pubmed: 13 9 2024
entrez: 13 9 2024
Statut: aheadofprint

Résumé

Patients with head and neck squamous cell carcinomas (HNSCC) often have poor outcomes due to suboptimal risk-management and treatment strategies; yet integrating novel prognostic biomarkers into clinical practice is challenging. Here, we report the presence of multinucleated giant cells (MGC) - a type of macrophages - in tumors from patients with HNSCC, which are associated with a favorable prognosis in treatment-naive and preoperative-chemotherapy-treated patients. Importantly, MGC density increased in tumors following preoperative therapy, suggesting a role of these cells in the anti-tumoral response. To enable clinical translation of MGC density as a prognostic marker, we developed a deep-learning model to automate its quantification on routinely stained pathological whole slide images. Finally, we used spatial transcriptomic and proteomic approaches to describe the MGC-related tumor microenvironment and observed an increase in central memory CD4 T cells. We defined an MGC-specific signature resembling to TREM2-expressing mononuclear tumor associated macrophages, which co-localized in keratin tumor niches.

Identifiants

pubmed: 39270324
pii: 748455
doi: 10.1158/2159-8290.CD-24-0018
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Gregoire Gessain (G)

Institut Gustave Roussy, France.

Ahmed-Amine Anzali (AA)

Institut Gustave Roussy, France.

Marvin Lerousseau (M)

Mines ParisTech, Paris, France.

Kevin Mulder (K)

Institut Gustave Roussy, Villejuif, France.

Mathilde Bied (M)

Institut Gustave Roussy, France.

Anne Auperin (A)

Institut Gustave Roussy, Villejuif, France.

Daniel Stockholm (D)

PSL Research University, Paris, France.

Nicolas Signolle (N)

Institut Gustave Roussy, Villejuif, France.

Farah Sassi (F)

Institut Gustave Roussy, France.

Maria Eugenia Marques Da Costa (ME)

Gustave Roussy Cancer Institute, INSERM U1015, Université Paris-Saclay, Villejuif, France.

Antonin Marchais (A)

Institut Gustave Roussy, Villejuif, France.

Alexandre Sayadi (A)

Beaujon Hospital, Clichy, France.

Daniela Weidner (D)

Universitätsklinikum Erlangen, Germany.

Stefan Uderhardt (S)

University Hospital Erlangen, Germany.

Quentin Blampey (Q)

University of Paris-Saclay, Gif-sur-Yvette, 91190, France.

Sumanth Reddy Nakkireddy (SR)

Mayo Clinic, Jacksonville, Florida, United States.

Sophie Broutin (S)

Institut Gustave Roussy, Villejuif, France.

Charles-Antoine Dutertre (CA)

Institut Gustave Roussy, Paris, France.

Pierre Busson (P)

CNRS - Gustave Roussy - Univ. Paris-Saclay, Villejuif, France.

Thomas Walter (T)

Mines ParisTech, Paris, France.

Alix Marhic (A)

Institut Gustave Roussy, France.

Antoine Moya-Plana (A)

Institut Gustave Roussy, France.

Joanne Guerlain (J)

Institut Gustave Roussy, France.

Ingrid Breuskin (I)

Institut Gustave Roussy, Villejuif, France.

Odile Casiraghi (O)

Institut Gustave Roussy, Villejuif, France.

Philippe Gorphe (P)

Institut Gustave Roussy, Villejuif, France.

Marion Classe (M)

Institut Gustave Roussy, France.

Jean-Yves Scoazec (JY)

Institut Gustave Roussy, Villejuif, Ile de France, France.

Camille Bleriot (C)

Institut Gustave Roussy, Villejuif, France.

Florent Ginhoux (F)

Singapore Immunology Network Agency for Science, Technology, and Research, Singapore, Singapore.

Classifications MeSH